BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 18956293)

  • 1. Mechanisms of disease progression in nonalcoholic fatty liver disease.
    Jou J; Choi SS; Diehl AM
    Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
    Choi SS; Diehl AM
    Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities.
    Gambino R; Musso G; Cassader M
    Antioxid Redox Signal; 2011 Sep; 15(5):1325-65. PubMed ID: 20969475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic steatohepatitis pathogenesis: role of repair in regulating the disease progression.
    Jung Y; Diehl AM
    Dig Dis; 2010; 28(1):225-8. PubMed ID: 20460916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of nonalcoholic steatohepatitis (NASH).
    Ma X; Li Z
    Chin J Dig Dis; 2006; 7(1):7-11. PubMed ID: 16412031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.
    Richardson MM; Jonsson JR; Powell EE; Brunt EM; Neuschwander-Tetri BA; Bhathal PS; Dixon JB; Weltman MD; Tilg H; Moschen AR; Purdie DM; Demetris AJ; Clouston AD
    Gastroenterology; 2007 Jul; 133(1):80-90. PubMed ID: 17631134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease.
    Nobili V; Carpino G; Alisi A; Franchitto A; Alpini G; De Vito R; Onori P; Alvaro D; Gaudio E
    Hepatology; 2012 Dec; 56(6):2142-53. PubMed ID: 22467277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
    Sanyal AJ; Campbell-Sargent C; Mirshahi F; Rizzo WB; Contos MJ; Sterling RK; Luketic VA; Shiffman ML; Clore JN
    Gastroenterology; 2001 Apr; 120(5):1183-92. PubMed ID: 11266382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis.
    Rombouts K; Marra F
    Dig Dis; 2010; 28(1):229-35. PubMed ID: 20460917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in nonalcholic fatty liver disease.
    Greenfield V; Cheung O; Sanyal AJ
    Curr Opin Gastroenterol; 2008 May; 24(3):320-7. PubMed ID: 18408460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activin A in nonalcoholic fatty liver disease.
    Yndestad A; Haukeland JW; Dahl TB; Halvorsen B; Aukrust P
    Vitam Horm; 2011; 85():323-42. PubMed ID: 21353887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective.
    Lackner C
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):223-31. PubMed ID: 21476917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human hepatocellular in vitro model to investigate steatosis.
    Gómez-Lechón MJ; Donato MT; Martínez-Romero A; Jiménez N; Castell JV; O'Connor JE
    Chem Biol Interact; 2007 Jan; 165(2):106-16. PubMed ID: 17188672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.
    Wanless IR; Shiota K
    Semin Liver Dis; 2004 Feb; 24(1):99-106. PubMed ID: 15085490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
    Schuppan D; Schattenberg JM
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.